Marken ups ultra-low temp transportation services for growing cell and gene market

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/Pablo_K)
(Image: Getty/Pablo_K)
Marken has expanded its cryogenic services to support demand driven by an increasing amount of global cell and gene therapy clinical trials – a market projected to reach $363m by 2022.

The expanded network now includes facilities in Philadelphia, New York, Los Angeles, Miami, London, Frankfurt, Singapore, and Tokyo, with Johannesburg expected to join later this year.

According to the company​, the larger network of liquid nitrogen filling locations and packaging fleet will enable Marken to meet client demand for the ultra-low temperature transportation services required for cell, gene, and immunotherapy-based medicines.

Recent reports​ project the global gene therapy market to reach $363m by 2022. Driving this growth is an estimated 2,200 clinical trials focusing on oncology, rare diseases, Parkinson's, HIV, severe combined immunodeficiencies (SCID), and hemophilia. Most of these trials are expected to be conducted in the US, Europe, Canada, and China, according to the report.

Marken also recently added​ three cities to its clinical logistics network in Latin America. Additional cities are in a test phase and are expected to be added in the future.

Related news

Show more

Related products

show more

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Related suppliers

Follow us

Featured Events

View more

Products

View more

Webinars